Funded Tech Companies
Leap Therapeutics
Leap Therapeutics is a biopharmaceutical company, based in Cambridge. Financial backing was provided by private investors and Winklevoss Capital.
Company Overview
Company Name
Leap Therapeutics
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
47 Thorndike St
Cambridge, MA 02141
USA
Cambridge, MA 02141
USA
Phone
Website
Email Address
Not Recorded
Company Background Information
Overview
Leap's most advanced clinical candidate, sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. FL-301, is a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Leap also has FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
10/9/2025
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Douglas Onsi
Company Investors
- Winklevoss Capital
Browse more funded tech companies:
Share this article
About Our VC Transaction Database
This tech company profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs